Author: Stanley Crooke

Stanley Crooke, MD, PhD is founder, chairman and CEO of Isis Pharmaceuticals. Isis (NASDAQ: [[ticker:ISIS]]) is a development stage biopharmaceutical company that is focused on a new paradigm in drug discovery, antisense oligonucleotides. Since Dr. Crooke and his colleagues founded Isis in 1989, the company completed its initial public offering in May 1991, and has reported broad progress in antisense technology and its rapid conversion to therapeutic product opportunities. Isis was the first company to commercialize an antisense drug and has achieved a number of important corporate collaborative relationships. In 2006, Dr. Crooke was named in Nature Biotechnology as one of biotechnology’s influential individuals. Dr. Crooke is currently a member of the San Diego State University BioScience Center Scientific Advisory Board, the Current Drugs Advisory Board, and the Editorial Board of Gene Therapy and Molecular Biology. He is also Editor-in-Chief of Current Opinion in Anticancer Drugs and Section Editor for Biologicals and Immunologicals for Expert Opinion on Investigational Drugs. Prior to founding Isis, Dr. Crooke was President of Research and Development for SmithKline Beckman Corporation (SKB). He also coordinated the research and development activities of SKB including its instruments, diagnostics, animal health and clinical laboratory businesses. Prior to joining SKB, Dr. Crooke helped establish the anticancer drug discovery and development program at Bristol Myers, which succeeded in bringing to market a significant number of drugs. During his career, Dr. Crooke has supervised the development of 19 drugs currently on the market and others in development. In addition to his involvement in the pharmaceutical industry, Dr. Crooke also maintains active academic positions. He is an adjunct professor at San Diego State University, and has won a number of teaching awards. He has authored over 400 publications and has edited 20 books. Dr. Crooke is active in molecular and cellular biology and pharmacology of antisense oligonucleotides. Dr. Crooke received his M.D. and Ph.D. from Baylor College of Medicine, Houston, Texas and his B.S. in Pharmacy from Butler University, Indianapolis, Indiana.